Company intelligence / Profile preview

Arcion Therapeutics

Baltimore, Maryland, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Arcion's lead candidate ARC-4558 (0.1% clonidine gel) showed positive results in Phase 2b trials for painful diabetic neuropathy, with significantly greater pain reduction compared to placebo. The FDA granted Fast Track designation for this program, which was poised to enter Phase 3 studies.[5][7][9]

Therapeutic areas: Neurology
Modalities: Small moleculestopical formulations
Industry: Biotech

Drug pipeline

5 assets

CNTX-4975

Phase 3

Indications: Knee osteoarthritis

4 more assets in the full pipeline.

Request access →

Partnerships

Anesiva, Inc. (merged)

Beyond the preview

Go deeper on Arcion Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arcion Therapeutics.

Explore the full profile